AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1(Original). A method of treating acne and/or hirsutism comprising the step of delivering to a mammal in need thereof a composition comprising a compound of formula I, or a tautomer thereof, and a physiologically compatible carrier, wherein formula I is:



I

wherein:

R^1 and R^2 are selected from the group consisting of H, alkyl, substituted alkyl, OH, O(alkyl), O(substituted alkyl), O(Acetyl), aryl, substituted aryl, heterocyclic ring, substituted heterocyclic ring, alkylaryl, substituted alkylaryl, alkylheteroaryl, substituted alkylheteroaryl, 1-propynyl, substituted 1-propynyl, 3-propynyl, and substituted 3-propynyl;

or R^1 and R^2 are joined to form a ring selected from the group consisting of $-CH_2(CH_2)_nCH_2-$, $-CH_2CH_2C(CH_3)_2CH_2CH_2-$, $-O(CH_2)_mCH_2-$, $-O(CH_2)_pO-$, $-CH_2CH_2OCH_2CH_2-$, $-CH_2CH_2N(H)CH_2CH_2-$, and $-CH_2CH_2N(alkyl)CH_2CH_2-$;

m is an integer from 1 to 4;

n is an integer from 1 to 5;

p is an integer from 1 to 4;

or R^1 and R^2 form a double bond to $C(CH_3)_2$, C(cycloalkyl), O, or C(cycloether);

R^3 is selected from the group consisting of H, OH, NH_2, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_6 alkenyl, substituted C_3 to C_6 alkenyl, alkynyl, substituted alkynyl, and COR^A;

R^A is selected from the group consisting of H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, and substituted C_1 to C_3 aminoalkyl;

R^4 is selected from the group consisting of H, halogen, CN, NH_2, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_1 to C_6 alkoxy, substituted C_1 to C_6 alkoxy, C_1 to C_6 aminoalkyl, and substituted C_1 to C_6 aminoalkyl;

R^5 is selected from the group consisting of a), b) and c):

a) a substituted benzene ring having the structure:



X is selected from the group consisting of halogen, OH, CN, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 thioalkyl, substituted C_1 to C_3 thioalkyl, S(O)alkyl, $S(O)_2$alkyl, C_1 to C_3 aminoalkyl, substituted C_1 to C_3 aminoalkyl, NO_2, C_1 to C_3 perfluoroalkyl, substituted C_1 to C_3 perfluoroalkyl, 5 or 6 membered heterocyclic ring having 1 to 3 heteroatoms, $CONH_2$, $CSNH_2$, CNHNHOH, CNH_2NOH, CNHNOH, COR^B, CSR^B, $OCOR^B$, and NR^CCOR^B;

R^B is selected from the group consisting of H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, aryl, substituted aryl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, and substituted C_1 to C_3 aminoalkyl;

R^C is H, C_1 to C_3 alkyl, or substituted C_1 to C_3 alkyl;

Y and Z are independently selected from the group consisting of H, halogen, CN, NO_2, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_4 alkyl, substituted C_1 to C_4 alkyl, C_1 to C_3 thioalkyl, and substituted C_1 to C_3 thioalkyl;

b) a five or six membered heterocyclic ring comprising 1, 2, or 3 heteroatoms selected from the group consisting of O, S, SO, SO_2 and NR^6 and having one or two

independent substituents from the group consisting of H, halogen, CN, NO_2, C_1 to C_4 alkyl, substituted C_1 to C_4 alkyl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, substituted C_1 to C_3 aminoalkyl, COR^D, CSR^D, and NR^ECOR^D;

R^D is H, NH_2, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, aryl, substituted aryl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, or substituted C_1 to C_3 aminoalkyl;

R^E is H, C_1 to C_3 alkyl, or substituted C_1 to C_3 alkyl;

R^6 is H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, or C_1 to C_4CO_2alkyl; or

c) an indol-4-yl, indol-7-yl or benzo-2-thiophene moiety, wherein said moiety is optionally substituted by from 1 to 3 substituents selected from the group consisting of halogen, alkyl, substituted alkyl, CN, NO_2, alkoxy, substituted alkoxy, and CF_3;

Q^1 is S, NR^7, or CR^8R^9;

R^7 is selected from the group consisting of CN, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic ring, substituted heterocyclic ring, acyl, substituted acyl, aroyl, substituted aroyl, SO_2CF_3, OR^{11}, and $NR^{11}R^{12}$;

R^8 and R^9 are independent substituents selected from the group consisting of H, alkyl, substituted alkyl, acyl, substituted acyl, aroyl, substituted aroyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic ring, substituted heterocyclic ring, NO_2, CN, and CO_2R^{10};

R^{10} is C_1 to C_3 alkyl or substituted C_1 to C_3 alkyl;

or CR^8R^9 comprise a six membered ring having the structure:



R^{11} and R^{12} are independently selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclic ring, substituted heterocyclic ring, acyl, substituted acyl, aroyl, substituted aroyl, sulfonyl, and substituted sulfonyl; or a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.

2(Original). The method according to Claim 1, wherein:
R^1 and R^2 are joined to form a $-CH_2(CH_2)_nCH_2-$ ring;
n is 3;
R^3 and R^4 are H;
R^5 is the substituted benzene ring having the structure:



X is selected from the group consisting of halogen, CN, $CONH_2$, $CSNH_2$, COR^B, CSR^B, C_1 to C_3 alkoxy, C_1 to C_3 alkyl, NO_2, C_1 to C_3 perfluoroalkyl, 5 membered heterocyclic ring comprising 1 to 3 heteroatoms, and C_1 to C_3 thioalkyl;

R^B is C_1 to C_3 aminoalkyl or substituted C_1 to C_3 aminoalkyl, wherein said aminoalkyl is NH(alkyl) or $N(alkyl)_2$;

Y is selected from the group consisting of H, halogen, CN, NO_2, C_1 to C_3 alkoxy, C_1 to C_4 alkyl, and C_1 to C_3 thioalkyl.

3(Original). The method according to Claim 1, wherein:
R^1 and R^2 are joined to form the $-CH_2(CH_2)_nCH_2-$ ring;
n is 3;
R^3 and R^4 are H;

R^5 is the five membered ring having the structure:



U is O, S, or NR^6;

X' is selected from the group consisting of halogen, CN, NO_2, $CONH_2$, $CSNH_2$, COR^B, CSR^B, C_1 to C_3 alkyl, and C_1 to C_3 alkoxy;

R^B is C_1 to C_3 aminoalkyl or substituted C_1 to C_3 aminoalkyl, wherein said aminoalkyl is NH(alkyl) or $N(alkyl)_2$;

Y' is selected from the group consisting of H, halogen, and C_1 to C_4 alkyl, wherein said halogen is F.

4(Original). The method according to Claim 1, wherein:

R^1 and R^2 are joined to form a $-CH_2(CH_2)_nCH_2-$ ring;

n is 3;

R^3 and R^4 are H;

R^5 is the six membered ring having the structure:



X^1 is N or CX^2;

X^2 is halogen, CN, $CONH_2$, $CSNH_2$, COR^B, CSR^B, or NO_2;

R^B is C_1 to C_3 aminoalkyl or substituted C_1 to C_3 aminoalkyl, wherein said aminoalkyl is NH(alkyl) or $N(alkyl)_2$.

5(Original). The method according to claim 1, wherein:

R^1 and R^2 are alkyl or substituted alkyl;

R^3 is H.

6(Original). The method according to claim 1, wherein:

R^1 and R^2 are joined to form a ring selected from the group consisting of $-CH_2(CH_2)_nCH_2-$, $-CH_2CH_2C(CH_3)_2CH_2CH_2-$, $-O(CH_2)_mCH_2-$, $-O(CH_2)_pO-$, $-CH_2CH_2OCH_2CH_2-$, $-CH_2CH_2N(H)CH_2CH_2-$, and $-CH_2CH_2N(alkyl)CH_2CH_2-$;

R^3 is H.

7(Original). The method according to claim 1, wherein:

R^3 is H;

Q^1 is S or NR^7.

8(Original). The method according to claim 1, wherein the compound is delivered orally.

9(Previously Presented). The method according to claim 1, wherein said compound of formula I is selected from the group consisting of 5'-(3-Chlorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)-thione, 3-(1',2'-Dihydro-2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)benzonitrile, 4-1',2'-Dihydro-2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-2-thiophenecarbonitrile, 3-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-5-fluorobenzonitrile, 4-Methyl-5-(1,2-dihydro-2-thioxospiro[cyclohexane-1,3-[3H]-indol]-5-yl)-2-thiophenethioamide, 5-(1,2-Dihydro-2-thioxospiro[cyclopentane-1,3-[3H]indol]-5'-yl)-1H-pyrrole-2-carbonitrile, 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-1-(tert-butoxycarbonyl)-pyrrole-2-carbonitrile, 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-1-H-pyrrole-2-carbonitrile, 5-(2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-1-methyl-pyrrole-2-carbonitrile, 5-(1,2-Dihydro-2-thioxospiro[cyclopentane-1,3-[3H]indol]-5-yl)-3thiophenecarbonitrile, 5-(1,2-Dihydro-thioxospiro[cyclopentane-1,3-[3H]indol]-5-yl)-2thiophenecarbonitrile, 5-(3-Fluoro-4-methoxyphenyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-thione, 5-(2-Amino-5-pyrimidinyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-thione, 3-(1,2-Dihydro-2-thioxospiro[cyclopentane-1,3-[3H]indol]-5-yl)-5-

fluorobenzonitrile, 5-(3-chlorophenyl)-3,3-dimethyl-1,3-dihydro-2H-indole-2-thione, 3-Benzyl-5-(3-chlorophenyl)-3-methyl-1,3-dihydro-2H-indole-2-thione, 4-(3,3-dimethyl-2-thioxo-2,3-dihydro-1H-indol-5-yl)-2-furonitrile, 5-(3-methoxyphenyl)-3,3-dimethyl-1,3-dihydro-2H-indole-2-thione, 3-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-4-fluorobenzonitrile, 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-3-pyridinecarbonitrile, 5-(3,4-Difluorophenyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-thione, 5-(5-Chloro-2-thienyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-thione, 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-3-furancarbonitrile, 5-(3-Chloro-4-fluorophenyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-thione, 5-(3-Chloro-5-fluorophenyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-thione, 5-(3,5-Difluorophenyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-thione, 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-4-propyl-2-thiophenecarbonitrile, 5-(3-Fluoro-4-nitrophenyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-thione, 4-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-2-furancarbonitrile, 5"-(3-Chlorophenyl)spiro[cyclobutane-1,3"-[3H]indol]-2"(1"H)-thione, 5"-(2-Chlorophenyl)spiro[cyclohexane-1,3"-[3H]indol]-2"(1"H)-thione, 5"-(4-Chlorophenyl)spiro[cyclohexane-1,3"-[3H]indol]-2"(1"H)-thione, 5-(1",2"-Dihydro-2"-thioxospiro[cyclohexane-1,3"-[3H]indol]-5"-yl)-4-methyl-2-thiophenecarbonitrile, 5-(1",2"-Dihydro-2"-thioxospiro[cyclohexane-1,3"-[3H]indol]-5"-yl)-2-thiophenecarbonitrile, 5"-(3-Fluorophenyl)spiro[cyclohexane-1,3"-[3H]indol]-2"(1"H)-thione, 5-(3-Hydroxyphenyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-thione, 5-(3-chlorophenyl)-3,3-diethyl-1,3-dihydro-2H-indole-2-thione, 5-(4-Fluoro-3-(trifluoromethyl)phenyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-thione, 4-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-2-fluorobenzonitrile, 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-4-n-butyl-2-thiophenecarbonitrile, 5-(3-Fluoro-5-methoxyphenyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-thione, 5-(3-Chlorophenyl)-N-hydroxyspiro[cyclohexane-1,3'-[3H]indol]-2-amine, N-(Acetyloxy)-5'-(3-chlorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2"amine, 5'-(3-Fluorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)-one oxime, 5'-(2-

Fluorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)-one oxime, 5'-(4-Fluorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)-one oxime, 5'-(3,4-difluorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)-one oxime, 5'-(3-methoxyphenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)-one oxime, 5'-(3-nitrophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)-one oxime, 5'-(3-cyanophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)-one oxime, 3-(1',2'-Dihydro-2'-(hydroxyimino)spiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-5-fluorobenzonitrile, 5-(Spiro[cyclohexane-1,3'-[3H]indol]-2'-(hydroxyimino)-5'-yl)-4-methyl-2-thiophenecarbonitrile, 5-(Spiro[cyclohexane-1,3'-[3H]indol]-2'-(hydroxyimino)-5'-yl)-2-thiophenecarbonitrile, 4-(Spiro[cyclohexane-1,3'-[3H]indol]-2'-(hydroxyimino)-5'-yl)-2-thiophenecarbonitrile, 5-(Spiro[cyclohexane-1,3'-[3H]indol]-2'-(hydroxyimino)-5'-yl)-1H-pyrrole-1-methyl-2-carbonitrile, 5-(spiro[cyclohexane-1,3'-[3H]indol]-2'-(hydroxyimino)-5'-yl)-1H-pyrrole-2-carbonitrile, 4-(Spiro[cyclohexane-1,3'-[3H]indol]-2'(acetoxyimino)-5'-yl)-2-thiophenecarbonitrile, 3-Fluoro-N'-hydroxy-5-(2'-(hydroxyamino)spiro[cyclohexane-1,3'-[3H]indol]-5'-yl)benzenecarboximidamide, N'-Hydroxy-5-(spiro[cyclohexane-1,3'-[3H]indol]-2'-(hydroxyimino)-5'-yl)-4-methyl-2-thiophenecarboximidamide, N'-Hydroxy-4-(spiro[cyclohexane-1,3'-[3H]indol]-2'-hydroxyimino)-5'-yl-2-thiophenecarboximidamide, N'-Hydroxy-5-(spiro[cyclohexane-1,3'-[3H]indol]-2'-(hydroxyimino)-5'-yl)-2-thiophenecarboxidamide, 5'-(3-Chlorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'-ylidenecyanamide, 5'-(3-Cyano-5-fluorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'-ylidenecyanamide, 5'-(5-Cyano-1H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2-ylidenecyanamide, 5'-(5-Cyano-thiophen-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-ylidenecyanamide, 5'-(5-Cyano-3-methyl-thiophen-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-ylidenecyanamide, 5'-(5-Cyano-thiophen-3-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-ylidenecyanamide, 3-(2'-Cyanomethylene-spiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-5-fluoro-benzonitrile, 5-(2'-Cyanomethylene-spiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-1H-pyrrole-2-carbonitrile, 5-(2'-Cyanomethylene-spiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-1-methyl-1H-pyrrole-2-

carbonitrile, 5-(2'-Cyanomethylene-spiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-thiophene-2-carbonitrile, 5-(2'-Cyanomethylene-spiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-4-methyl-thiophene-2-carbonitrile, and 4-(2'-Cyanomethylene-spiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-thiophene-2-carbonitrile, or a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.

10(Previously Presented). The method according to claim 1, wherein said compound is 5'-(5-Cyano-1-methyl-1H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-ylidenecyanamide, or a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.

11(Original). A method of treating acne and/or hirsutism comprising the step of delivering to a mammal in need thereof a composition comprising a compound of formula II, or a tautomer thereof, and a physiologically compatible carrier, wherein formula II is:



II

wherein:

R^{11} is selected from the group consisting of H, acyl, substituted acyl, aroyl, substituted aroyl, sulfonyl, and substituted sulfonyl;

R^5 is (i), (ii), or (iii):

(i) a substituted benzene ring having the structure:



wherein:

X is selected from the group consisting of halogen, CN, $CONH_2$, $CSNH_2$, CONHalkyl, CSNHalkyl, $CON(alkyl)_2$, $CSN(alkyl)_2$, CNHNHOH, CNH_2NOH, C_1 to C_3 alkoxy, C_1 to C_3 alkyl, NO_2, C_1 to C_3 perfluoroalkyl, 5 membered heterocyclic ring comprising 1 to 3 heteroatoms, and C_1 to C_3 thioalkyl;

Y is selected from the group consisting of H, halogen, CN, NO_2, C_1 to C_3 alkoxy, C_1 to C_4 alkyl, and C_1 to C_3 thioalkyl;

(ii) a five membered ring having the structure:



wherein:

U is O, S, or NR^6;

R^6 is H, C_1 to C_3 alkyl, or C_1 to C_4 CO_2alkyl;

X' is selected from the group consisting of halogen, CN, NO_2, $CONH_2$, CNHNHOH, CNH_2NOH, $CSNH_2$, CONHalkyl, CSNHalkyl, $CON(alkyl)_2$, $CSN(alkyl)_2$, C_1 to C_3 alkyl, and C_1 to C_3 alkoxy;

Y' is selected from the group consisting of H, F, and C_1 to C_4 alkyl; or

(iii) a six membered ring having the structure:



wherein:

X^1 is N or CX^2;

X^2 is halogen, CN, $CONH_2$, $CSNH_2$, CONHalkyl, CSNHalkyl, $CON(alkyl)_2$, $CSN(alkyl)_2$ or NO_2;

or a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.

12(Original). The method according to claim 11, wherein R^5 is said five membered ring and U is O or S.

13(Original). A method of treating acne and/or hirsutism comprising the step of delivering to a mammal in need thereof a composition comprising a compound of formula III, or a tautomer thereof, and a physiologically compatible carrier, wherein formula III is:



III

wherein:

R^5 is (i), (ii), or (iii):

(i) a substituted benzene ring having the structure:



wherein:

X is selected from the group consisting of halogen, CN, $CONH_2$, $CSNH_2$, CONHalkyl, CSNHalkyl, $CON(alkyl)_2$, $CSN(alkyl)_2$, CNHNOH, C_1 to C_3 alkoxy, C_1 to C_3 alkyl, NO_2, C_1 to C_3 perfluoroalkyl, 5 membered heterocyclic ring comprising 1 to 3 heteroatoms, and C_1 to C_3 thioalkyl;

Y is selected from the group consisting of H, halogen, CN, NO_2, C_1 to C_3 alkoxy, C_1 to C_4 alkyl, and C_1 to C_3 thioalkyl;

(ii) a five membered ring having the structure:



wherein:

U is O, S, or NR^6;

R^6 is H, C_1 to C_3 alkyl, or C_1 to C_4 CO_2alkyl;

X' is selected from the group consisting of halogen, CN, NO_2, $CONH_2$, $CSNH_2$, CONHalkyl, CSNHalkyl, $CON(alkyl)_2$, $CSN(alkyl)_2$, C_1 to C_3 alkyl, and C_1 to C_3 alkoxy;

Y' is selected from the group consisting of H, F and C_1 to C_4 alkyl; or

(iii) a six membered ring having the structure:



wherein:

X^1 is N or CX^2;

X^2 is halogen, CN, $CONH_2$, $CSNH_2$, CONHalkyl, CSNHalkyl, $CON(alkyl)_2$, $CSN(alkyl)_2$ or NO_2;

or a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.

14(Original). The method according to claim 13, wherein R^5 is the five membered ring (ii) and U is O or S.

15(Original). A method of treating acne and/or hirsutism comprising the step of delivering to a mammal in need thereof a composition comprising a compound of formula IV, or a tautomer thereof, and a physiologically compatible carrier, wherein formula IV is:



IV

wherein:

R^8 is selected from the group consisting of H, CO_2R^{10}, acyl, substituted acyl, aroyl, substituted aroyl, alkyl, substituted alkyl, and CN;

R^{10} is C_1 to C_3 alkyl;

R^5 is (i), (ii), or (iii):

(i) a substituted benzene ring having the structure:



wherein:

X is selected from the group consisting of halogen, CN, $CONH_2$, $CSNH_2$, CONHalkyl, CSNHalkyl, $CON(alkyl)_2$, $CSN(alkyl)_2$, CNHNOH, C_1 to C_3 alkoxy, C_1 to C_3 alkyl, NO_2, C_1 to C_3 perfluoroalkyl, 5 membered heterocyclic ring comprising 1 to 3 heteroatoms, and C_1 to C_3 thioalkyl;

Y is selected from the group consisting of H, halogen, CN, NO_2, C_1 to C_3 alkoxy, C_1 to C_4 alkyl, and C_1 to C_3 thioalkyl;

(ii) a five membered ring having the structure:



wherein:

U is O, S, or NR^6;

R^6 is H, C_1 to C_3 alkyl, or C_1 to C_4 CO_2alkyl;

X' is selected from the group consisting of halogen, CN, NO_2, $CONH_2$, $CSNH_2$, CONHalkyl, CSNHalkyl, $CON(alkyl)_2$, $CSN(alkyl)_2$, C_1 to C_3 alkyl, and C_1 to C_3 alkoxy;

Y' is selected from the group consisting of H, F and C_1 to C_4 alkyl;

(iii) a six membered ring having the structure:



wherein:

X^1 is N or CX^2;

X^2 is halogen, CN, $CONH_2$, $CSNH_2$, CONHalkyl, CSNHalkyl, $CON(alkyl)_2$, $CSN(alkyl)_2$ or NO_2;

or a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.

16(Original). The method according to claim 15, wherein R^5 is the five-membered ring (ii) and U is O or S.

17(Original). A method of treating acne and hirsutism comprising the step of delivering to a mammal in need thereof a composition comprising a compound of formula V, or a tautomer thereof, and a physiologically compatible carrier, wherein formula V is:



V

R^5 is (i), (ii), or (iii):

(i) a substituted benzene ring having the structure:



wherein:

X is selected from the group consisting of halogen, CN, $CONH_2$, $CSNH_2$, CONHalkyl, CSNHalkyl, $CON(alkyl)_2$, $CSN(alkyl)_2$, CNHNOH, C_1 to C_3 alkoxy, C_1 to C_3 alkyl, NO_2, C_1 to C_3 perfluoroalkyl, 5 membered heterocyclic ring comprising 1 to 3 heteroatoms, and C_1 to C_3 thioalkyl;

Y is selected from the group consisting of H, halogen, CN, NO_2, C_1 to C_3 alkoxy, C_1 to C_4 alkyl, and C_1 to C_3 thioalkyl;

(ii) a five membered ring having the structure:



wherein:

U is O, S, or NR^6;

R^6 is H, C_1 to C_3 alkyl, or C_1 to C_4 CO_2alkyl;

X' is selected from the group consisting of halogen, CN, NO_2, $CONH_2$, $CSNH_2$, CONHalkyl, CSNHalkyl, $CON(alkyl)_2$, $CSN(alkyl)_2$, C_1 to C_3 alkyl, and C_1 to C_3 alkoxy;

Y' is selected from the group consisting of H, F, and C_1 to C_4 alkyl;

(iii) a six membered ring having the structure:



wherein:

X^1 is N or CX^2;

X^2 is halogen, CN, $CONH_2$, $CSNH_2$, CONHalkyl, CSNHalkyl, $CON(alkyl)_2$, $CSN(alkyl)_2$ or NO_2;

or a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.

18-19(Canceled).

20(Previously Presented). The method according to claim 22, wherein:

R^1 and R^2 are alkyl or substituted alkyl;

R^3 is H.

21(Previously Presented). The method according to claim 22, wherein:

R^1 and R^2 are joined to form a ring selected from the group consisting of $-CH_2(CH_2)_nCH_2-$, $-CH_2CH_2C(CH_3)_2CH_2CH_2-$, $-O(CH_2)_mCH_2-$, $-O(CH_2)_pO-$, $-CH_2CH_2OCH_2CH_2-$, $-CH_2CH_2N(H)CH_2CH_2-$, and $-CH_2CH_2N(alkyl)CH_2CH_2-$;

R^3 is H.

22(Previously Presented). The method according to claim 22, wherein:

R^3 is H;

Q^1 is S or NR^7.

23(Previously Presented). A method of conditioning the skin comprising the step of delivering to a mammal in need thereof a composition comprising:

(i) a skin conditioning component; and

(ii) a compound of formula I, or a tautomer thereof:



I

wherein:

R^1 and R^2 are selected from the group consisting of H, alkyl, substituted alkyl, OH, O(alkyl), O(substituted alkyl), O(Acetyl), aryl, substituted aryl, heterocyclic ring, substituted heterocyclic ring, alkylaryl, substituted alkylaryl, alkylheteroaryl, substituted alkylheteroaryl, 1-propynyl, substituted 1-propynyl, 3-propynyl, and substituted 3-propynyl;

or R^1 and R^2 are joined to form a ring selected from the group consisting of $-CH_2(CH_2)_nCH_2-$, $-CH_2CH_2C(CH_3)_2CH_2CH_2-$, $-O(CH_2)_mCH_2-$, $-O(CH_2)_pO-$, $-CH_2CH_2OCH_2CH_2-$, $-CH_2CH_2N(H)CH_2CH_2-$, and $-CH_2CH_2N(alkyl)CH_2CH_2-$;

m is an integer from 1 to 4;

n is an integer from 1 to 5;

p is an integer from 1 to 4;

or R^1 and R^2 form a double bond to $C(CH_3)_2$, C(cycloalkyl), O, or C(cyclocther);

R^3 is selected from the group consisting of H, OH, NH_2, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_6 alkenyl, substituted C_3 to C_6 alkenyl, alkynyl, substituted alkynyl, and COR^A;

R^A is selected from the group consisting of H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, and substituted C_1 to C_3 aminoalkyl;

R^4 is selected from the group consisting of H, halogen, CN, NH_2, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_1 to C_6 alkoxy, substituted C_1 to C_6 alkoxy, C_1 to C_6 aminoalkyl, and substituted C_1 to C_6 aminoalkyl;

R^5 is selected from the group consisting of a), b) and c):

a) a substituted benzene ring having the structure:



X is selected from the group consisting of halogen, OH, CN, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3

thioalkyl, substituted C_1 to C_3 thioalkyl, S(O)alkyl, $S(O)_2$alkyl, C_1 to C_3 aminoalkyl, substituted C_1 to C_3 aminoalkyl, NO_2, C_1 to C_3 perfluoroalkyl, substituted C_1 to C_3 perfluoroalkyl, 5 or 6 membered heterocyclic ring comprising 1 to 3 heteroatoms, $CONH_2$, $CSNH_2$, CNHNHOH, CNH_2NOH, CNHNOH, COR^B, CSR^B, $OCOR^B$, and NR^CCOR^B;

R^B is selected from the group consisting of H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, aryl, substituted aryl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, and substituted C_1 to C_3 aminoalkyl;

R^C is H, C_1 to C_3 alkyl, or substituted C_1 to C_3 alkyl;

Y and Z are independently selected from the group consisting of H, halogen, CN, NO_2, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_4 alkyl, substituted C_1 to C_4 alkyl, C_1 to C_3 thioalkyl, and substituted C_1 to C_3 thioalkyl;

b) a five or six membered heterocyclic ring comprising 1, 2, or 3 heteroatoms selected from the group consisting of O, S, SO, SO_2 and NR^6 and having one or two independent substituents from the group consisting of H, halogen, CN, NO_2, C_1 to C_4 alkyl, substituted C_1 to C_4 alkyl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, substituted C_1 to C_3 aminoalkyl, COR^D, CSR^D, and NR^ECOR^D;

R^D is H, NH_2, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, aryl, substituted aryl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, or substituted C_1 to C_3 aminoalkyl;

R^E is H, C_1 to C_3 alkyl, or substituted C_1 to C_3 alkyl;

R^6 is H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, or C_1 to C_4CO_2alkyl; or

c) an indol-4-yl, indol-7-yl or benzo-2-thiophene moiety, wherein said moiety is optionally substituted by from 1 to 3 substituents selected from the group consisting of halogen, alkyl, substituted alkyl, CN, NO_2, alkoxy, substituted alkoxy, and CF_3;

Q^1 is S, NR^7, or CR^8R^9;

R^7 is selected from the group consisting of CN, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl,

heterocyclic ring, substituted heterocyclic ring, acyl, substituted acyl, aroyl, substituted aroyl, SO_2CF_3, OR^{11}, and $NR^{11}R^{12}$;

R^8 and R^9 are independent substituents selected from the group consisting of H, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic ring, substituted heterocyclic ring, NO_2, CN, and CO_2R^{10};

R^{10} is C_1 to C_3 alkyl or substituted C_1 to C_3 alkyl;

or CR^8R^9 comprise a six membered ring having the structure:



R^{11} and R^{12} are independently selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclic ring, substituted heterocyclic ring, acyl, substituted acyl, aroyl, substituted aroyl, sulfonyl, and substituted sulfonyl;

or a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.

24(Previously Presented). The method according to claim 23 wherein said compound of formula I is selected from the group consisting of 5'-(3-Chlorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)-thione, 3-(1',2'-Dihydro-2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)benzonitrile, 4-1',2'-Dihydro-2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-2-thiophenecarbonitrile, 3-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-5-fluorobenzonitrile, 4-Methyl-5-(1,2-dihydro-2-thioxospiro[cyclohexane-1,3-[3H]-indol]-5-yl)-2-thiophenethioamide, 5-(1,2-Dihydro-2-thioxospiro[cyclopentane-1,3-[3H]indol]-5'-yl)-1H-pyrrole-2-carbonitrile, 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-1-(tert-butoxycarbonyl)-pyrrole-2-carbonitrile, 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-1-H-pyrrole-2-carbonitrile, 5-(2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-1-methyl-pyrrole-2-carbonitrile, 5-(1,2-Dihydro-2-thioxospiro[cyclopentane-1,3-[3H]indol]-5-yl)-

3thiophenecarbonitrile, 5-(1,2-Dihydro-thioxospiro[cyclopentane-1,3-[3H]indol]-5-yl)-2thiophenecarbonitrile, 5-(3-Fluoro-4-methoxyphenyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-thione, 5-(2-Amino-5-pyrimidinyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-thione, 3-(1,2-Dihydro-2-thioxospiro[cyclopentane-1,3-[3H]indol]-5-yl)-5-fluorobenzonitrile, 5-(3-chlorophenyl)-3,3-dimethyl-1,3-dihydro-2H-indole-2-thione, 3-Benzyl-5-(3-chlorophenyl)-3-methyl-1,3-dihydro-2H-indole-2-thione, 4-(3,3-dimethyl-2-thioxo-2,3-dihydro-1H-indol-5-yl)-2-furonitrile, 5-(3-methoxyphenyl)-3,3-dimethyl-1,3-dihydro-2H-indole-2-thione, 3-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-4-fluorobenzonitrile, 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-3-pyridinecarbonitrile, 5-(3,4-Difluorophenyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-thione, 5-(5-Chloro-2-thienyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-thione, 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-3-furancarbonitrile, 5-(3-Chloro-4-fluorophenyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-thione, 5-(3-Chloro-5-fluorophenyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-thione, 5-(3,5-Difluorophenyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-thione, 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-4-propyl-2-thiophenecarbonitrile, 5-(3-Fluoro-4-nitrophenyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-thione, 4-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-2-furancarbonitrile, 5"-(3-Chlorophenyl)spiro[cyclobutane-1,3"-[3H]indol]-2"(1"H)-thione, 5"-(2-Chlorophenyl)spiro[cyclohexane-1,3"-[3H]indol]-2"(1"H)-thione, 5"-(4-Chlorophenyl)spiro[cyclohexane-1,3"-[3H]indol]-2"(1"H)-thione, 5-(1",2"-Dihydro-2"-thioxospiro[cyclohexane-1,3"-[3H]indol]-5"-yl)-4-methyl-2-thiophenecarbonitrile, 5-(1",2"-Dihydro-2"-thioxospiro[cyclohexane-1,3"-[3H]indol]-5"-yl)-2-thiophenecarbonitrile, 5"-(3-Fluorophenyl)spiro[cyclohexane-1,3"-[3H]indol]-2"(1"H)-thione, 5-(3-Hydroxyphenyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-thione, 5-(3-chlorophenyl)-3,3-diethyl-1,3-dihydro-2H-indole-2-thione, 5-(4-Fluoro-3-(trifluoromethyl)phenyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-thione, 4-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-2-fluorobenzonitrile,

5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-4-n-butyl-2-thiophenecarbonitrile, 5-(3-Fluoro-5-methoxyphenyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-thione, 5-(3-Chlorophenyl)-N-hydroxyspiro[cyclohexane-1,3'-[3H]indol]-2-amine, N-(Acetyloxy)-5'-(3-chlorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2"amine, 5'-(3-Fluorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)-one oxime, 5'-(2-Fluorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)-one oxime, 5'-(4-Fluorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)-one oxime, 5'-(3,4-difluorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)-one oxime, 5'-(3-methoxyphenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)-one oxime, 5'-(3-nitrophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)-one oxime, 5'-(3-cyanophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)-one oxime, 3-(1',2'-Dihydro-2'-(hydroxyimino)spiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-5-fluorobenzonitrile, 5-(Spiro[cyclohexane-1,3'-[3H]indol]-2'-(hydroxyimino)-5'-yl)-4-methyl-2-thiophenecarbonitrile, 5-(Spiro[cyclohexane-1,3'-[3H]indol]-2'-(hydroxyimino)-5'-yl)-2-thiophenecarbonitrile, 4-(Spiro[cyclohexane-1,3'-[3H]indol]-2'-(hydroxyimino)-5'-yl)-2-thiophenecarbonitrile, 5-(Spiro[cyclohexane-1,3'-[3H]indol]-2'-(hydroxyimino)-5'-yl)-1H-pyrrole-1-methyl-2-carbonitrile, 5-(spiro[cyclohexane-1,3'-[3H]indol]-2'-(hydroxyimino)-5'-yl)-1H-pyrrole-2-carbonitrile, 4-(Spiro[cyclohexane-1,3'-[3H]indol]-2'(acetoxyimino)-5'-yl)-2-thiophenecarbonitrile, 3-Fluoro-N'-hydroxy-5-(2'-(hydroxyamino)spiro[cyclohexane-1,3'-[3H]indol]-5'-yl)benzenecarboximidamide, N'-Hydroxy-5-(spiro[cyclohexane-1,3'-[3H]indol]-2'-(hydroxyimino)-5'-yl)-4-methyl-2-thiophenecarboximidamide, N'-Hydroxy-4-(spiro[cyclohexane-1,3'-[3H]indol]-2'-hydroxyimino)-5'-yl-2-thiophenecarboximidamide, N'-Hydroxy-5-(spiro[cyclohexane-1,3'-[3H]indol]-2'-(hydroxyimino)-5'-yl)-2-thiophenecarboxidamide, 5'-(3-Chlorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'-ylidenecyanamide, 5'-(3-Cyano-5-fluorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'-ylidenecyanamide, 5'-(5-Cyano-1H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2-ylidenecyanamide, 5'-(5-Cyano-thiophen-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-ylidenecyanamide, 5'-(5-

Cyano-3-methyl-thiophen-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-ylidenecyanamide, 5'-(5-Cyano-thiophen-3-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-ylidenecyanamide, 3-(2'-Cyanomethylene-spiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-5-fluoro-benzonitrile, 5-(2'-Cyanomethylene-spiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-1H-pyrrole-2-carbonitrile, 5-(2'-Cyanomethylene-spiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-1-methyl-1H-pyrrole-2-carbonitrile, 5-(2'-Cyanomethylene-spiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-thiophene-2-carbonitrile, 5-(2'-Cyanomethylene-spiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-4-methyl-thiophene-2-carbonitrile, and 4-(2'-Cyanomethylene-spiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-thiophene-2-carbonitrile, or a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.

25(Original). The method according to claim 23, wherein said compound is 5'-(5-Cyano-1-methyl-1H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-ylidenecyanamide, or a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.

26(New). The method according to claim 1, wherein said prodrug is an ester or carbamate.

27(New). The method according to claim 23, wherein said prodrug is an ester or carbamate.